Jessica E Pittman1, Robin C Johnson, Stephanie D Davis. 1. Division of Pediatric Pulmonology, University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599, USA. jessica_pittman@med.unc.edu
Abstract
BACKGROUND: Recent studies have shown the presence of lung disease in even asymptomatic infants with cystic fibrosis (CF). While pulmonary function testing (PFT) is often used to follow progression of lung disease and guide treatment in older children with CF, little data is available on change in infant PFTs in young children with CF. OBJECTIVE: To determine change in infant PFTs before and after antibiotic therapy for pulmonary exacerbation in infants with CF. METHODS: Retrospective cohort study of infants with CF who underwent clinically indicated infant PFTs before and after antibiotic therapy for CF pulmonary exacerbation at the University of North Carolina at Chapel Hill. RESULTS: Pre- and post-antibiotics PFT data was available on 11 infants with CF, with a mean age of 102 weeks at time of first PFT. The majority of infants were symptomatic prior to antibiotics, and showed statistically significant improvement in clinical parameters following treatment. Prior to antibiotics, PFTs showed evidence of substantial obstructive disease (mean z-scores for FVC, FEV(0.5) , and FEF(25-75) of -1.81, -3.06, and -4.5, respectively) and air-trapping/hyperinflation (mean z-scores for FRCpleth, RV, and RV/TLC of 8.86, 7.1, and 3.31, respectively). Following antibiotics, all of the above parameters showed statistically significant improvement. DISCUSSION: We have shown a statistically significant improvement in infant PFT measures following antibiotic therapy in a cohort of 11 infants with CF, which paralleled improvement in clinical parameters. Though infant PFTs showed improvement, they remained abnormal in the majority of subjects, with persistent air-trapping and hyperinflation after antibiotic therapy. Our findings suggest that infant PFTs are sensitive to acute clinical changes in children with CF, and may be a useful tool in managing infants with CF.
BACKGROUND: Recent studies have shown the presence of lung disease in even asymptomatic infants with cystic fibrosis (CF). While pulmonary function testing (PFT) is often used to follow progression of lung disease and guide treatment in older children with CF, little data is available on change in infant PFTs in young children with CF. OBJECTIVE: To determine change in infant PFTs before and after antibiotic therapy for pulmonary exacerbation in infants with CF. METHODS: Retrospective cohort study of infants with CF who underwent clinically indicated infant PFTs before and after antibiotic therapy for CF pulmonary exacerbation at the University of North Carolina at Chapel Hill. RESULTS: Pre- and post-antibiotics PFT data was available on 11 infants with CF, with a mean age of 102 weeks at time of first PFT. The majority of infants were symptomatic prior to antibiotics, and showed statistically significant improvement in clinical parameters following treatment. Prior to antibiotics, PFTs showed evidence of substantial obstructive disease (mean z-scores for FVC, FEV(0.5) , and FEF(25-75) of -1.81, -3.06, and -4.5, respectively) and air-trapping/hyperinflation (mean z-scores for FRCpleth, RV, and RV/TLC of 8.86, 7.1, and 3.31, respectively). Following antibiotics, all of the above parameters showed statistically significant improvement. DISCUSSION: We have shown a statistically significant improvement in infant PFT measures following antibiotic therapy in a cohort of 11 infants with CF, which paralleled improvement in clinical parameters. Though infant PFTs showed improvement, they remained abnormal in the majority of subjects, with persistent air-trapping and hyperinflation after antibiotic therapy. Our findings suggest that infant PFTs are sensitive to acute clinical changes in children with CF, and may be a useful tool in managing infants with CF.
Authors: Shahid I Sheikh; Frederick R Long; Robert Flucke; Nancy A Ryan-Wenger; Don Hayes; Karen S McCoy Journal: Lung Date: 2015-03-12 Impact factor: 2.584
Authors: The Thanh-Diem Nguyen; Lena P Thia; Ah-Fong Hoo; Andrew Bush; Paul Aurora; Angie Wade; Jane Chudleigh; Sooky Lum; Janet Stocks Journal: Thorax Date: 2013-09-26 Impact factor: 9.139
Authors: Harm A W M Tiddens; Michael Puderbach; Jose G Venegas; Felix Ratjen; Scott H Donaldson; Stephanie D Davis; Steven M Rowe; Scott D Sagel; Mark Higgins; David A Waltz Journal: Pediatr Pulmonol Date: 2014-12-30
Authors: Emily M DeBoer; Julia S Kimbell; Kaci Pickett; Joseph E Hatch; Kathryn Akers; John Brinton; Graham L Hall; Louise King; Fiona Ramanauskas; Tim Rosenow; Stephen M Stick; Harm A Tiddens; Thomas W Ferkol; Sarath C Ranganathan; Stephanie D Davis Journal: Respir Physiol Neurobiol Date: 2021-06-19 Impact factor: 1.931